JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 0-1 Year Treasury Bond ETF
SHV
|
+$3.85B |
| 2 |
iShares Core US Aggregate Bond ETF
AGG
|
+$1.5B |
| 3 |
JPMorgan BetaBuilders Canada ETF
BBCA
|
+$1.21B |
| 4 |
Chevron
CVX
|
+$1.08B |
| 5 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$986M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 1-3 Year Treasury Bond ETF
SHY
|
+$3.61B |
| 2 |
Occidental Petroleum
OXY
|
+$1.36B |
| 3 |
Merck
MRK
|
+$913M |
| 4 |
Visa
V
|
+$801M |
| 5 |
AT&T
T
|
+$771M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 27.95% |
| 2 | Technology | 12.9% |
| 3 | Financials | 12.36% |
| 4 | Healthcare | 9.31% |
| 5 | Consumer Discretionary | 8.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
ACOR
3326
DELISTED
Acorda Therapeutics
ACOR
| $1.78M | ﹤0.01% |
2,004
-19
| -0.9% | -$23.3K |
2014 Q2
20 quarters
|
|
3327
Scansource
SCSC
$1.23B
| $1.77M | ﹤0.01% |
54,641
-2,980
| -5% | -$101K |
2015 Q4
14 quarters
|
|
3328
PUT
Trupanion
TRUP
$1.08B
| $1.77M | ﹤0.01% |
+50,800
| New | +$1.67M |
2019 Q2
0 quarters
|
|
|
CNCE
3329
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $1.77M | ﹤0.01% |
150,592
+2,097
| +1% | +$22.6K |
2017 Q4
6 quarters
|
|
|
SGI
3330
Somnigroup International
SGI
$14.4B
| $1.76M | ﹤0.01% |
97,600
+13,292
| +16% | +$214K |
2013 Q2
24 quarters
|
|
|
VIAB
3331
PUT
DELISTED
Viacom Inc. Class B
VIAB
| $1.76M | ﹤0.01% |
60,000
-294,800
| -83% | -$8.62M |
2018 Q3
3 quarters
|
|
3332
Sunoco
SUN
$13.7B
| $1.75M | ﹤0.01% |
55,835
-98,597
| -64% | -$3.03M |
2014 Q3
19 quarters
|
|
3333
Virtus Investment Partners
VRTS
$874M
| $1.75M | ﹤0.01% |
16,624
+10,943
| +193% | +$1.22M |
2014 Q3
19 quarters
|
|
3334
Park National Corp
PRK
$3.26B
| $1.75M | ﹤0.01% |
17,778
+2,460
| +16% | +$239K |
2017 Q4
6 quarters
|
|
3335
Zymeworks
ZYME
$1.84B
| $1.75M | ﹤0.01% |
79,296
+60,472
| +321% | +$1.11M |
2019 Q1
1 quarter
|
|
|
BRY
3336
DELISTED
Berry Corp
BRY
| $1.73M | ﹤0.01% |
167,896
+28,529
| +20% | +$323K |
2018 Q3
3 quarters
|
|
|
SDRL
3337
DELISTED
Seadrill Limited Common Stock
SDRL
| $1.73M | ﹤0.01% |
413,632
-624,739
| -60% | -$4.1M |
2013 Q2
24 quarters
|
|
3338
Forrester Research
FORR
$214M
| $1.72M | ﹤0.01% |
36,464
+9,630
| +36% | +$464K |
2016 Q2
12 quarters
|
|
3339
Mercantile Bank Corp
MBWM
$1.02B
| $1.72M | ﹤0.01% |
53,664
+4,610
| +9% | +$151K |
2016 Q2
12 quarters
|
|
3340
Nordic American Tanker
NAT
$1.74B
| $1.72M | ﹤0.01% |
768,521
+579,347
| +306% | +$1.25M |
2015 Q1
17 quarters
|
|
3341
State Street SPDR Nuveen ICE Municipal Bond ETF
TFI
$2.84B
| $1.72M | ﹤0.01% |
34,172
+20,316
| +147% | +$1.01M |
2013 Q2
24 quarters
|
|
3342
Diodes
DIOD
$4.96B
| $1.71M | ﹤0.01% |
48,567
-10,688
| -18% | -$378K |
2013 Q2
24 quarters
|
|
3343
Baytex Energy
BTE
$3.28B
| $1.7M | ﹤0.01% |
1,105,415
+14,474
| +1% | +$26.3K |
2013 Q2
24 quarters
|
|
3344
FS Bancorp
FSBW
$347M
| $1.7M | ﹤0.01% |
67,126
+44,702
| +199% | +$1.12M |
2017 Q2
8 quarters
|
|
3345
Genesco
GCO
$391M
| $1.7M | ﹤0.01% |
40,056
+2,668
| +7% | +$118K |
2013 Q2
24 quarters
|
|
3346
Gyre Therapeutics
GYRE
$751M
| $1.7M | ﹤0.01% |
29,565
-895
| -3% | -$55.9K |
2018 Q2
4 quarters
|
|
|
GWPH
3347
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $1.69M | ﹤0.01% |
9,927
+5,826
| +142% | +$1.01M |
2014 Q4
18 quarters
|
|
3348
Cleveland-Cliffs
CLF
$6.99B
| $1.69M | ﹤0.01% |
161,919
-103,606
| -39% | -$1.02M |
2013 Q2
24 quarters
|
|
3349
Howard Hughes
HHH
$4.38B
| $1.68M | ﹤0.01% |
13,419
+959
| +8% | +$98.2K |
2015 Q4
14 quarters
|
|
|
RST
3350
DELISTED
ROSETTA STONE INC
RST
| $1.68M | ﹤0.01% |
74,391
+4,206
| +6% | +$101K |
2016 Q4
10 quarters
|
|
Similar funds
JP Morgan Chase's Q2 2019 Portfolio in Review
As of Q2 2019, JP Morgan Chase held 6,226 positions worth $511B, up 4.5% from $490B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
JP Morgan Chase's Q2 2019 filing shows 458 new, 2,668 increased, 2,116 reduced and 420 closed positions. Its largest new stake was Corteva: 13,119,143 shares worth $388M. The largest sale was iShares 1-3 Year Treasury Bond ETF, an estimated $3.61B.
By sector, the portfolio is most concentrated in Miscellaneous at 28% of assets, up from 27% a quarter earlier, followed by Technology and Financials.
- JP Morgan Chase's largest Q2 2019 buy was Corteva: 13,119,143 shares worth $388M.
- JP Morgan Chase added most to iShares 0-1 Year Treasury Bond ETF in Q2 2019, an estimated $3.85B increase.
- JP Morgan Chase's biggest Q2 2019 reduction was iShares 1-3 Year Treasury Bond ETF, cutting an estimated $3.61B.
- JP Morgan Chase fully exited Goldcorp Inc in Q2 2019, selling an estimated $131M.
- JP Morgan Chase's ten largest holdings make up 16% of its $511B portfolio in Q2 2019.
- JP Morgan Chase opened 458 new positions and closed 420 in Q2 2019.
- JP Morgan Chase's portfolio value rose 4.5% quarter-over-quarter to $511B.
Based on JP Morgan Chase's 13F filing for Q2 2019, filed 7 Aug 2019.